What is proinsulin and how is it used in clinical practice?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Proinsulin: Clinical Definition and Use

Proinsulin is the precursor molecule to insulin that is NOT routinely measured in clinical practice for diabetes management, but serves specific diagnostic roles in evaluating hypoglycemia and distinguishing between endogenous and exogenous insulin causes 1.

What is Proinsulin?

Proinsulin is the single-chain precursor protein synthesized by pancreatic β-cells that is cleaved to produce insulin and C-peptide. In healthy individuals, proinsulin comprises only a small fraction of circulating insulin-related peptides, as it is normally processed efficiently within the β-cells before secretion 2, 3.

Clinical Applications

Primary Indication: Hypoglycemia Evaluation

The main clinical utility of proinsulin measurement is in the diagnostic workup of hypoglycemic disorders, particularly when investigating suspected insulinomas or other causes of endogenous hyperinsulinism 4.

Diagnostic criteria during hypoglycemia (plasma glucose <55 mg/dL):

  • Proinsulin ≥5.0 pmol/L indicates endogenous hyperinsulinism
  • Must be measured alongside insulin (≥3.0 µU/mL) and C-peptide (≥0.6 ng/mL)
  • An elevated proinsulin-to-insulin ratio strongly suggests an islet cell tumor 1, 4

When to Measure Proinsulin

During spontaneous or provoked hypoglycemia episodes:

  • Obtain simultaneous measurements of glucose, insulin, C-peptide, proinsulin, and β-hydroxybutyrate
  • Screen for oral hypoglycemic agents
  • Administer 1.0 mg glucagon IV and observe glucose response 4

If spontaneous episodes cannot be captured:

  • Conduct a supervised 72-hour fast
  • Measure the same panel when glucose drops below 55 mg/dL 4

NOT Recommended for Routine Use

The 2023 Diabetes Care guidelines explicitly state that routine testing for proinsulin in people with diabetes or at risk for diabetes is NOT recommended 1. These assays are primarily useful for research purposes, not clinical management of diabetes.

Key points:

  • Do not use proinsulin to diagnose type 1 vs type 2 diabetes (use C-peptide instead if needed)
  • Do not use proinsulin to assess insulin resistance in polycystic ovary syndrome
  • Do not use proinsulin for routine diabetes monitoring or treatment decisions 1

Important Clinical Caveats

Insulinoma Detection

In patients with documented endogenous hyperinsulinemic hypoglycemia, the absence of elevated proinsulin makes an islet cell tumor highly unlikely, and alternative explanations should be sought 1. The proinsulin criterion (≥5.0 pmol/L) may be met even when insulin levels are borderline, making it a sensitive marker 4.

Post-Bariatric Surgery Hypoglycemia

Elevated proinsulin levels can occur in nesidioblastosis following gastric bypass surgery, typically manifesting in the postprandial period many months after surgery 4.

Measurement Considerations

  • Proinsulin levels must be interpreted in the context of simultaneous glucose levels
  • Renal insufficiency can affect interpretation
  • Modern LC-MS/MS assays can distinguish intact proinsulin from partially processed forms (des-31,32 and des-64,65 proinsulin) 5

Pitfalls to Avoid

Do not order proinsulin for:

  • Routine diabetes screening or diagnosis
  • Assessing β-cell function in established diabetes (use C-peptide)
  • Evaluating insulin resistance
  • Differentiating diabetes types in typical presentations 1

Do order proinsulin when:

  • Investigating unexplained hypoglycemia in a seemingly well individual
  • Suspecting an insulinoma based on clinical presentation
  • Evaluating for factitious hypoglycemia (to distinguish endogenous from exogenous insulin) 4

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.